An Open-label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (Pegasys) as Monotherapy or in Combination With Ribavirin (Copegus) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Trial Profile

An Open-label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (Pegasys) as Monotherapy or in Combination With Ribavirin (Copegus) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2013

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 16 May 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01853254).
    • 02 May 2009 Additional location identified as reported by Roche records.
    • 19 Jun 2008 500 patients are expected to be enrolled according to Roche.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top